On the 10th of August, pharmaceutical company Zydus Cadila announced that it had introduced Remdesivir under the logo called Remdac, used to treat patients suffering from severe COVID-19 symptoms, in the Indian market. With a value of Rs 2,800 consistent with a hundred mg vial, Remdac is the cheapest Remdesivir logo in India, Zydus Cadila said in a regulatory presentation.
The company said the drug would be obtained in India through the group’s strong distribution chain, achieving government and personal hospitals that treat coVID-19 patients.
“Remdac is the most affordable drug because we need to give patients access to this essential drug in the COVID-19 remedy,” said Dr. Sharvil Patel, Managing Director of Cadila Healthcare.
During this pandemic, the company’s efforts have focused on supporting others in this fitness crisis, whether through the progression of vaccines, increased production and distribution of critical drugs and therapies, the provision of diagnostic tests or the exploration of new remedies. options, Patel added.
In June of this year, Zydus entered into a non-exclusive agreement with Gilead Sciences Inc. to manufacture and Remdesivir, the experimental drug, which obtained emergency use authorization from the U.S. Food and Drug Administration (USFDA) to treat patients with severe symptoms of COVID-19.
Follow our live blog for updates on the new coronavirus pandemic
The active pharmaceutical element (API) of the drug evolved and was manufactured in the group’s API production plants in Gujarat.
Zydus Cadila candidate ZyCov-D vaccine is now in Phase II trials.
The shares of Cadila Healthcare, the group’s indexed entity, were listed at 387 rupees on BSE, 0.44% above its previous close.
Essential podcast about coronavirus Who will be the vaccines first ?; Government reviews standard operating procedures for air transport